Homeopathic Drug Product Safety, Quality, and Transparency Act
Key claim: HR7050 would establish safety, quality, and transparency requirements for homeopathic drug products, referred to the House Committee on Energy and Commerce in January 2026.
Abstract
(HR7050 · 119th Congress) Latest action (2026-01-14): Referred to the House Committee on Energy and Commerce.
Why this matters
Homeopathic drug products have historically been marketed in the U.S. under FDA guidance rather than a dedicated statutory framework, leaving safety and labeling standards uneven compared with conventional OTC drugs. HR7050 would codify safety, quality, and transparency requirements, which if enacted could change what manufacturers must disclose and what consumers see on labels. The bill is at an early stage (introduced, committee referral) and does not yet alter current FDA enforcement practice.